Cargando…
Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy – Interrupt or Continue Treatment – The Role of Immunohistochemical Examination
Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) and anti-programmed death receptor-1/ligand-1 (anti-PD-1/anti-PD-L1) caused a breakthrough in oncology and significantly improved therapeutic outcomes in cancer patients. ICIs generate a specific react...
Autores principales: | Cybulska-Stopa, Bożena, Gruchała, Andrzej, Niemiec, Maciej |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873039/ https://www.ncbi.nlm.nih.gov/pubmed/31762755 http://dx.doi.org/10.1159/000504130 |
Ejemplares similares
-
Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2019) -
Systemic treatment in patients with malignant pleural mesothelioma – real life experience
por: Ziółkowska, Barbara, et al.
Publicado: (2022) -
Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023) -
Pancytopenia associated with clonazepam
por: Bautista-Quach, Marnelli A, et al.
Publicado: (2010) -
Pancytopenia: An Etiological Profile
por: Raphael, Vandana, et al.
Publicado: (2012)